Atherosclerosis
Therapeutic area
Vascular Medicine
Rare disease
No
- Definition
- A disease characterized by the build-up of fatty material and calcium deposition in the arterial wall resulting in partial or complete occlusion of the arterial lumen.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Atherosclerosis
- Therapeutic area
- Vascular Medicine
- atherosclerosis
- atherosclerosis of artery
- Severity
- Severe
- Cardiology
- Vascular Medicine
- MONDO ID
- MONDO:0005311
- Parent condition
- MONDO:0002277
Related records
Broader conditions (7)
- Arterial disorder
- Arteriosclerosis disorder
- Cardiovascular disorder
- Disease
- Disease by body system or component
- Human disease
- Vascular disorder
Narrower conditions (9)
- Aortic atherosclerosis
- Arteriolosclerosis
- Arteriosclerosis obliterans
- Atherosclerotic cardiovascular disease
- Autoimmune atherosclerosis
- Cerebral atherosclerosis
- Coronary atherosclerosis
- Generalized atherosclerosis
- Renal artery atheroma
Trials (1,470)
- "Detection and Follow-up of Coronary Lesions in HeFH (DESTINY-FH Study)"
- "Immunoregulation in Atherosclerosis: A Single-Cell RNA Sequencing Study"
- [18F]AlF-NOTA-octreotide PET/MRI in Carotid Artery Disease
- 11C-PIB PET Study in MESA at Columbia University
- 12-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe
- 18F-fluorocholine PET-MR Imaging of Coronary Plaque Vulnerability
- 18F-Flutemetamol and Plaque Vulnerability
- 18F-Sodium Fluoride (18F-NaF) PET-CT Imaging to Identify Vulnerable Plaques in Patients With Diabetes
- 3D/4D Ultrasound Contrast Enhanced Imaging (CEUS) for Carotid Plaque Vulnerability
- 480 Biomedical Bioresorbable Scaffold System in the Treatment of de Novo Superficial Femoral Artery (SFA) Lesions
- 68Ga-FAPI PET/MR for Atherosclerosis
- 7 Year Follow-up Study of the DanRisk Population
- A Blinded Study Conducted at Multiple Centers Evaluating Various Doses of an Investigational Agent (BO-653) Against Placebo, for Safety and Effectiveness in Preventing Post-Angioplasty Blood Vessel Re-Closure (Restenosis) in Stented Vessels.
- A Clinical and Histological Analysis of Mesenchymal Stem Cells in Amputation
- A Clinical Study of IMC-001 for Injection in Improving Atherosclerotic Plaque Stability in Patients With Acute Coronary Syndrome.
- A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX)
- A Clinical Trial to Confirm Safety & Effectiveness of the SYNERGY 4.50 mm and 5.00 mm Stent for Treatment of Atherosclerotic Lesion(s)
- A Cohort Study on Cardiovascular and Cerebrovascular Outcomes
- A Coronary Computed Tomography Angiography-guided Intervention for High Risk Cardiovascular Disease Population in Rural China
- A Cross-sectional Study of Lipoprotein(a) Levels in Patients With Documented History of Atherosclerotic Cardiovascular Disease (ASCVD)
Approved drugs (7)
- Alirocumab
- Bempedoic acid
- Inclisiran sodium
- Lovastatin
- Niacin
- Pravastatin sodium
- Rosuvastatin calcium
Drugs in development (73)
- Acarbose Phase 3
- Aliskiren Phase 2
- Amlodipine Phase 3
- Anacetrapib Phase 3
- Ascorbic acid Phase 2
- Aspirin Phase 3
- Atorvastatin Phase 3
- Atreleuton Phase 2
- Baxdrostat Phase 1
- Benazepril Phase 3
- BMS-582949 Phase 2
- BMS-779788 Phase 1
- BMS-962476 Phase 1
- Canakinumab Phase 3
- Candesartan cilexetil Phase 3
- Carvedilol Phase 3
- Chlorothiazide Phase 3
- Chlorthalidone Phase 3
- Cilostazol Phase 3
- Clopidogrel Phase 3
Other linked drugs (2)
- Fluvastatin
- Sarpogrelate